# Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer

## TL;DR

This study identifies a potential new therapeutic target in ovarian cancer by exploring the MTDH-SND1 protein interaction and its link to cancer progression and cell death pathways.

## Contribution

The study introduces a proteomics-based strategy to identify MTDH-SND1 as a novel therapeutic vulnerability in high-grade serous ovarian cancer.

## Key findings

- Disrupting the MTDH-SND1 interaction dysregulates cancer progression and invasion pathways.
- Interference with the MTDH-SND1 complex enriches ferroptosis-related pathways in ovarian cancer cells.
- Combining C26A6 treatment with ferroptosis inducers enhances cancer cell inhibition in vitro.

## Abstract

High-grade serous ovarian cancer (HGSOC) is the most prevalent and aggressive subtype of ovarian cancer. The combination of late-stage diagnosis and the tendency to exhibit resistance to existing treatments highlights a critical gap in effective therapeutic options. There is thus a need for novel strategies for targeting HGSOC, particularly in its advanced stages. To address this gap, we developed a comprehensive atlas profiling both the proteome and phosphoproteome levels across a panel of nine ovarian cancer cell lines from different subtypes. Subsequent differential expression analysis between the KURAMOCHI and the other cell lines, followed by phosphosite analyses, proposed the MTDH protein as a potential target. Further functional analyses of MTDH and the interacting protein SND1 with RNA silencing, as well as targeting their interaction, revealed that disrupting this interaction leads to the dysregulation of several pathways associated with cancer progression and invasion. In particular, interference with the MTDH-SND1 complex was associated with enrichment of ferroptosis-related pathways. Moreover, combining C26A6 treatment with ferroptosis inducers produced enhanced inhibitory effects in ovarian cancer cells, suggesting a possible strategy for targeting cancer cell vulnerabilities in HGSOC, which warrants further investigation beyond in vitro models.

The online version contains supplementary material available at 10.1038/s41598-025-26913-1.